Structural and Functional Studies on the Interaction of Adenovirus Fiber Knobs and Desmoglein 2 |
| |
Authors: | Hongjie Wang Roma Yumul Hua Cao Liang Ran Xiaolong Fan Maximilian Richter Forrest Epstein Julie Gralow Chloe Zubieta Pascal Fender André Lieber |
| |
Affiliation: | University of Washington, Division of Medical Genetics, Seattle, Washington, USAa;University of Washington, Department of Pathology, Seattle, Washington, USAb;Beijing Normal University, Beijing, Chinac;Fred Hutchinson Cancer Research Center, Seattle, Washington, USAd;European Synchrotron Radiation Facility, Grenoble, Francee;Unit of Virus Host Cell Interactions, UMI3265, CNRS/EMBL/UJF, Grenoble, Francef |
| |
Abstract: | Human adenovirus (Ad) serotypes Ad3, Ad7, Ad11, and Ad14, as well as a recently emerged strain of Ad14 (Ad14p1), use the epithelial junction protein desmoglein 2 (DSG2) as a receptor for infection. Unlike Ad interaction with CAR and CD46, structural details for Ad binding to DSG2 are still elusive. Using an approach based on Escherichia coli expression libraries of random Ad3 and Ad14p1 fiber knob mutants, we identified amino acid residues that, when mutated individually, ablated or reduced Ad knob binding to DSG2. These residues formed three clusters inside one groove at the extreme distal end of the fiber knob. The Ad3 fiber knob mutant library was also used to identify variants with increased affinity to DSG2. We found a number of mutations within or near the EF loop of the Ad3 knob that resulted in affinities to DSG2 that were several orders of magnitude higher than those to the wild-type Ad3 knob. Crystal structure analysis of one of the mutants showed that the introduced mutations make the EF loop more flexible, which might facilitate the interaction with DSG2. Our findings have practical relevance for cancer therapy. We have recently reported that an Ad3 fiber knob-containing recombinant protein (JO-1) is able to trigger opening of junctions between epithelial cancer cells which, in turn, greatly improved the intratumoral penetration and efficacy of therapeutic agents (I. Beyer, et al., Clin. Cancer Res. 18:3340–3351, 2012; I. Beyer, et al., Cancer Res. 71:7080–7090, 2011). Here, we show that affinity-enhanced versions of JO-1 are therapeutically more potent than the parental protein in a series of cancer models. |
| |
Keywords: | |
|
|